Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020
November 09 2020 - 08:00AM
Business Wire
- Presentations Demonstrate Ability of Seagen
Antibody-Drug Conjugates to Elicit Immunogenic Cell Death Effect
Across Multiple Tumor Types -
- Data Features Seagen’s Sugar-Engineered
Antibodies as part of an Emerging, Innovative Immuno-Oncology
Pipeline -
Seagen Inc. (Nasdaq:SGEN) today announced the presentation of
immuno-oncology data from its broad pipeline of therapies at the
Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary
Annual Meeting 2020, taking place virtually November 9-14, 2020.
Six abstracts will highlight the company’s continued progress in
advancing innovative research for marketed and late-stage
antibody-drug conjugates (ADCs) and innovative empowered antibody
pipeline utilizing its proprietary sugar-engineering antibody (SEA)
technology.
Data presented at SITC will demonstrate how Seagen’s monomethyl
auristatin E (MMAE)-based ADCs induce immunogenic cell death (ICD)
by activating the innate immune cells and changing the tumor
microenvironment to a more inflammatory state thereby enhancing the
efficacy of other cancer immunotherapies. These findings will be
presented for tisotumab vedotin, ladiratuzumab vedotin and across
vedotin-based ADCs (Abstracts #617, #618 and #323).
“Our vedotin-based ADC research at SITC illustrates the impact
of immunogenic cell death on the tumor microenvironment,” said
Roger Dansey, M.D., Chief Medical Officer at Seagen. “Importantly,
these data support the mechanistic rationale for combining
vedotin-based ADCs with immuno-oncology therapies in the
clinic.”
Data will also be presented utilizing Seagen’s proprietary SEA
technology, which produces nonfucosylated antibodies that uniquely
enhance activity targeting key immune modulating receptors.
Preclinical data will be presented from SEA-TGT (Abstract #250), a
novel investigational nonfucosylated human IgG1 TIGIT antibody.
SEA-TGT is in an ongoing phase 1 clinical trial for patients with
solid tumors and lymphoma (NCT04254107). In addition, preclinical
data will be presented for SEA-CD40 (Abstract #438), a novel
investigational, nonfucosylated human IgG1 antibody targeted to
CD40, an immune stimulatory receptor found on antigen-presenting
cells. SEA-CD40 is in a phase 1 trial for pancreatic cancer in
combination with chemotherapy and a PD-1 inhibitor
(NCT02376699).
“We believe our immuno-oncology candidates have a best-in-class
potential, creating a strong foundation for our immunotherapy
pipeline,” said Scott Peterson, Ph.D., Senior Vice President of
Research at Seagen. “Data presented at SITC demonstrate that our
sugar-engineered antibodies are differentiated and have the
potential to improve efficacy and address unmet needs in
cancer.”
Data regarding ADCETRIS® (brentuximab vedotin) will be presented
demonstrating its ability to selectively target and kill
CD30-positive T regulatory cells (Tregs) that contribute to
resistance to cancer immunotherapies (Abstract #696). These data
support that ADCETRIS may have an immunomodulatory effect through
selective depletion of highly active Tregs.
The abstracts published in advance of the SITC Annual Meeting
can be found here. All data presentations will be available
on-demand starting on November 11, 2020.
Details of Seagen Presentations at SITC
Annual Meeting 2020:
Abstract Title
Abstract No.
Presentation
Type / Date
Presenter
Brentuximab vedotin, a CD30 targeting
antibody-drug conjugate, selectively depletes activated Tregs in
vitro and in vivo
#696
E-Poster /
November 11-14
B. Grogan
Tisotumab vedotin shows immunomodulatory
activity through induction of immunogenic cell death
#617
E-Poster /
November 11-14
E. Gray
Systemic administration of ladiratuzumab
vedotin alone or in combination with pembrolizumab results in
significant immune activation in the tumor microenvironment in
metastatic breast cancer patients
#323
E-Poster /
November 11-14
L. Pusztai
Synergy between SEA-CD40 and
chemotherapeutics drives curative anti-tumor activity in
pre-clinical models
#438
E-Poster /
November 11-14
W. Zeng
SEA-TGT is a nonfucosylated antibody with
distinct and amplified effector function activity that leverages
the dependencies of anti-TIGIT anti-tumor activity upon FcγR
engagement
#250
E-Poster /
November 11-14
A. Smith
Vedotin ADCs induce ER stress and elicit
hallmarks of ICD across multiple cancer indications
#618
E-Poster /
November 11-14
K. Klussman
About Seagen
Seagen is a global biotechnology company that discovers,
develops and commercializes transformative cancer medicines to make
a meaningful difference in people’s lives. Seagen is headquartered
in the Seattle, Washington area, and has locations in California,
Canada, Switzerland and the European Union. For more information on
the company’s marketed products and robust pipeline, visit
www.seagen.com and follow @SeagenGlobal on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are
forward-looking, such as those, among others, relating to the
ability of vedotin-based ADCs to enhance the efficacy of
immune-oncology therapies, the potential of the Company’s SEA-TGT
and SEA-CD40 product candidates and the potential of the Company’s
immunotherapy pipeline. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
difficulty and uncertainty of pharmaceutical product development,
the risk of adverse events or safety signals, the inability to show
sufficient activity in clinical trials and the possibility of
adverse regulatory actions. More information about the risks and
uncertainties faced by Seagen is contained under the caption “Risk
Factors” included in the Company’s Quarterly Report on Form 10-Q
for the quarter ended September 30, 2020 filed with the Securities
and Exchange Commission. Seagen disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201109005125/en/
Investors and Media: Peggy Pinkston (425) 527-4160
ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024